Enhertu is already approved as a second-line or later treatment for HER2-positive breast cancer, along with other indications ...
The FDA has delivered a Commissioner's National Priority Voucher (CNPV) to Johnson & Johnson for a combination regimen based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback